tocofersolan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4280	59-02-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tocophersolan .ALPHA.-TOCOPHEROL, D- alpha-tocopherol alpha-D-Tocopherol syntopherol ALPHA-TOCOPHEROL, D- .ALPHA.-TOCOPHEROL d-alpha-tocopherol alpha-tocopherol, dl- .Alpha.-tocopherol, DL- tocofersolan vedrop	A natural tocopherol and one of the most potent antioxidant tocopherols. It exhibits antioxidant activity by virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus. It has four methyl groups on the 6-chromanol nucleus. The natural d form of alpha-tocopherol is more active than its synthetic dl-alpha-tocopherol racemic mixture. Molecular weight: 430.72 Formula: C29H50O2 CLOGP: 12 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 29.46 ALOGS: -7.79 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tocophersolan
.ALPHA.-TOCOPHEROL, D-
alpha-tocopherol
alpha-D-Tocopherol
syntopherol
ALPHA-TOCOPHEROL, D-
.ALPHA.-TOCOPHEROL
d-alpha-tocopherol
alpha-tocopherol, dl-
.Alpha.-tocopherol, DL-
tocofersolan
vedrop

A natural tocopherol and one of the most potent antioxidant tocopherols. It exhibits antioxidant activity by virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus. It has four methyl groups on the 6-chromanol nucleus. The natural d form of alpha-tocopherol is more active than its synthetic dl-alpha-tocopherol racemic mixture.

Molecular weight: 430.72
Formula: C29H50O2
CLOGP: 12
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 29.46
ALOGS: -7.79
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	274.47	12.94	160	29523	24216	63435123
Muscle spasticity	162.06	12.94	110	29573	21684	63437655
Electric shock	111.02	12.94	36	29647	1284	63458055
Therapy cessation	107.33	12.94	99	29584	30358	63428981
Ear pain	103.90	12.94	105	29578	36013	63423326
Body temperature increased	97.74	12.94	103	29580	37089	63422250
Night sweats	85.95	12.94	110	29573	48704	63410635
Respiratory disorder	83.30	12.94	97	29586	38985	63420354
Chronic sinusitis	81.87	12.94	59	29624	12784	63446555
Back pain	79.82	12.94	288	29395	263857	63195482

Showing 1 to 10 of 149 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	160.06	17.44	67	10566	7654	34938644
Appendicolith	159.62	17.44	69	10564	8532	34937766
Appendicitis	126.76	17.44	70	10563	14737	34931561
Ventricular fibrillation	100.85	17.44	71	10562	22883	34923415
Fractional exhaled nitric oxide increased	96.78	17.44	28	10605	1054	34945244
Stress	93.66	17.44	76	10557	30271	34916027
Cardiogenic shock	89.27	17.44	70	10563	26548	34919750
Dry mouth	83.63	17.44	71	10562	30094	34916204
Infective pulmonary exacerbation of cystic fibrosis	74.74	17.44	38	10595	6763	34939535
Plantar fasciitis	74.56	17.44	27	10606	2089	34944209

Showing 1 to 10 of 51 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasticity	166.66	13.35	106	32602	21369	79690311
Therapy cessation	137.80	13.35	118	32590	37444	79674236
Appendicolith	137.17	13.35	68	32640	8483	79703197
Blood phosphorus increased	122.17	13.35	67	32641	10280	79701400
Electric shock	113.72	13.35	36	32672	1358	79710322
Ear pain	108.01	13.35	97	32611	32772	79678908
Macular degeneration	93.25	13.35	58	32650	11238	79700442
Toxicity to various agents	92.44	13.35	29	32679	421511	79290169
Respiratory disorder	91.20	13.35	102	32606	44754	79666926
Peripheral swelling	88.36	13.35	277	32431	269340	79442340

Showing 1 to 10 of 169 entries

Previous1 2 3 4 5…17Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A11HA08	ALIMENTARY TRACT AND METABOLISM VITAMINS OTHER PLAIN VITAMIN PREPARATIONS Other plain vitamin preparations
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:22587	antiviral agents
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:37700	protein kinase C inhibitors
CHEBI has role	CHEBI:50249	anticoagulants
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:50846	Immunologic factor
CHEBI has role	CHEBI:50855	antiatherogenic drug
CHEBI has role	CHEBI:76924	plant metabolites

Showing 1 to 10 of 15 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obstruction of bile duct	indication	30144000
Vitamin E deficiency	indication	54137008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.06	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glutathione S-transferase P	Enzyme	P09211	GSTP1_HUMAN		IC50	6.30		CHEMBL
Alpha-tocopherol transfer protein	Transporter	P49638	TTPA_HUMAN		Kd	5.62		CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001020	NDDF
009945	NDDF
10191-41-0	SECONDARY_CAS_RN
116776001	SNOMEDCT_US
11960	MMSL
159151	RXNORM
259666007	SNOMEDCT_US
4017771	VANDF
40928	MMSL
71406	PUBCHEM_CID

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
C-Nate DHA	HUMAN PRESCRIPTION DRUG LABEL	13	23359-105	CAPSULE, GELATIN COATED	30 [iU]	ORAL	unapproved drug other	15 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0798	CAPSULE, GELATIN COATED	30 [iU]	ORAL	UNAPPROVED DRUG OTHER	11 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0799	CAPSULE, GELATIN COATED	30 [iU]	ORAL	Unapproved drug other	11 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0812	CAPSULE, GELATIN COATED	30 [iU]	ORAL	Unapproved drug other	11 sections
CitraNatal Harmony 3.0	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0796	CAPSULE, GELATIN COATED	30 [iU]	ORAL	unapproved drug other	10 sections
CitraNatal Harmony 3.0	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0796	CAPSULE, GELATIN COATED	30 [iU]	ORAL	unapproved drug other	10 sections
CitraNatal Medley	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0896	CAPSULE, GELATIN COATED	15 [iU]	ORAL	unapproved drug other	10 sections
CitraNatal Medley	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0896	CAPSULE, GELATIN COATED	15 [iU]	ORAL	unapproved drug other	10 sections
Floriva	HUMAN PRESCRIPTION DRUG LABEL	16	52796-173	TABLET, CHEWABLE	20 [iU]	ORAL	UNAPPROVED DRUG OTHER	6 sections
Floriva	HUMAN PRESCRIPTION DRUG LABEL	16	52796-174	TABLET, CHEWABLE	20 [iU]	ORAL	UNAPPROVED DRUG OTHER	6 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next